KR20240093579A - 치료-내성 우울증을 포함한 우울증의 치료를 위한 2-플루오로데스클로로케타민 - Google Patents

치료-내성 우울증을 포함한 우울증의 치료를 위한 2-플루오로데스클로로케타민 Download PDF

Info

Publication number
KR20240093579A
KR20240093579A KR1020247015974A KR20247015974A KR20240093579A KR 20240093579 A KR20240093579 A KR 20240093579A KR 1020247015974 A KR1020247015974 A KR 1020247015974A KR 20247015974 A KR20247015974 A KR 20247015974A KR 20240093579 A KR20240093579 A KR 20240093579A
Authority
KR
South Korea
Prior art keywords
fdck
administered
treatment
depression
antidepressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247015974A
Other languages
English (en)
Korean (ko)
Inventor
이즈키엘 골란
Original Assignee
클리어마인드 메디신 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클리어마인드 메디신 인크. filed Critical 클리어마인드 메디신 인크.
Publication of KR20240093579A publication Critical patent/KR20240093579A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247015974A 2021-10-18 2022-10-18 치료-내성 우울증을 포함한 우울증의 치료를 위한 2-플루오로데스클로로케타민 Pending KR20240093579A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256728P 2021-10-18 2021-10-18
US63/256,728 2021-10-18
PCT/IB2022/060011 WO2023067505A1 (en) 2021-10-18 2022-10-18 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression

Publications (1)

Publication Number Publication Date
KR20240093579A true KR20240093579A (ko) 2024-06-24

Family

ID=84178934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015974A Pending KR20240093579A (ko) 2021-10-18 2022-10-18 치료-내성 우울증을 포함한 우울증의 치료를 위한 2-플루오로데스클로로케타민

Country Status (8)

Country Link
US (1) US20250032429A1 (https=)
EP (1) EP4419092A1 (https=)
JP (1) JP2024538015A (https=)
KR (1) KR20240093579A (https=)
CN (1) CN118401239A (https=)
AU (1) AU2022374097A1 (https=)
CA (1) CA3233107A1 (https=)
WO (1) WO2023067505A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094757A1 (en) * 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
CN119241381A (zh) * 2019-12-26 2025-01-03 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途

Also Published As

Publication number Publication date
US20250032429A1 (en) 2025-01-30
EP4419092A1 (en) 2024-08-28
CA3233107A1 (en) 2023-04-27
CN118401239A (zh) 2024-07-26
WO2023067505A1 (en) 2023-04-27
AU2022374097A1 (en) 2024-03-14
JP2024538015A (ja) 2024-10-18

Similar Documents

Publication Publication Date Title
Soyka et al. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision
Zdanys et al. A systematic review of off-label uses of memantine for psychiatric disorders
Haas et al. Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study
CN102292094B (zh) 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
KR20140136982A (ko) 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
Kim et al. The role of glutamate underlying treatment-resistant depression
EA010430B1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
Auriel et al. Methylphenidate for the treatment of Parkinson disease and other neurological disorders
Pabis et al. Pharmacotherapy of aggressive behavior
US6835728B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
Levin et al. Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion
Rozet Ketamine in depression and electroconvulsive therapy
KR20240093579A (ko) 치료-내성 우울증을 포함한 우울증의 치료를 위한 2-플루오로데스클로로케타민
JP2025504069A (ja) オキシトシンを使用した治療方法
Issa et al. Psychopharmacology for pain medicine
AU2012307535A1 (en) Combinations comprising a S1P receptor modulator
McIntyre et al. Psychotropic-induced weight gain: liability, mechanisms and treatment approaches
MXPA05000566A (es) Tratamiento de depresion secundaria al dolor (dsp).
KR20250053188A (ko) 주요 우울 장애의 애주번트 치료를 위한 울로타론트
AU2013201492A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
Frye et al. Antiepileptics in the Treatment of Alcohol Withdrawal and Alcohol Use Relapse Prevention
Depression Academic Highlights
Garner The Role of Ketamine in Depression
Jones et al. Glutamate Approaches Towards the Treatment of Mood Disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)